Professor Dr Bart Van Wijmeersch Neurologist, Immunologist #MultipleSclerosis Expert @ University MS Centre, Hasselt-Pelt, Belgium
Hasselt, Belgium
Joined March 2019
- Tweets1.8K
- Following816
- Followers2K
- Likes2.3K
Best wishes for a wonderful 2025!
May peace, love, good health and joy be your constant companions #happynewyear
What a big legacy, what a great researcher, what a great teacher, what a great visionary, what a great man… a true example and inspiration. We will miss you dearly. RIP 😔
Professor_Bart retweeted
Professor Giancarlo Comi stressed the importance of listening to individuals with MS, pointing out that their experiences are a crucial tool in assessing disease progression. Read ECTRIMS’ tribute to his extraordinary legacy 👉 bit.ly/3B1xFFc
#MSResearch #Neurology
Ook voor #ectrims2024 Dag 3 overloop en verduidelijk ik kort de belangrijkste topics (met een mooie afsluiter) in een korte video.
youtu.be/ULSfrX42W4k?si=8GTs…
Professor_Bart retweeted
Lebrun-Frenay: Preventive healthcare in multiple sclerosis will need to focus on lifestyle and Epstein-Barr vaccination. #ECTRIMS2024
Fox Rob (US): tolebrutinib vs placebo in nrSPMS (HERCULES trial)
- 6m CDP: 31% decreases risk on tolebr
- 3m CDP: 24% “
- 6m CDI: increased chance on tolebr
- brain atrophy: no difference 🤔
Hopes are up for a change for persons with SPMS 🤞🏻👏🏻💪🏻
#ECTRIMS2024
Jiwon Oh (US): tolebrutinib vs teriflunimode in RRMS (GEMINI trials).
- ARR : no difference!
- 6m CDW: 29% reduction on tolebr
- 3m CDW: 27% reduction on tolebr
- New Gd+ lesions are higher on tolebrutinib!
- T2 lesions: no difference
- good safety profile
#ECTRIMS2024
Chataway (UK): MS-stat2 study on simvastatin 80mg vs placebo in SPMS.
Large phase 3 trial, unfortunately no significant effect on confirmed progression 🤷🏻♂️
#ECTRIMS2024
Kowalec (US) effect of genetic predisposition for depression on disease activity in #MS.
Higher risk of relapse and EDSS progression in persons with higher predisposition for depression!
Importance of comorbidity on MS disease course!
#ECTRIMS2024
Abdelhak: effect of fingolimod and anti-CD20 treatment on sGFAP (z-scores) evolution & subsequent effect on PIRA in RRMS pts.
Lowering Z-GFAP in first two years of treatment decreases PIRA risk in subsequent years by 44 (aCD20)-55%(fingo) sNFL does not add effect
#ECTRIMS2024
Nourbakhsh (US): prospective study on anti-CD20 ‘induction’ in RRMS:
6 months treatment only.
19 pts study…but nice results. Risk of reoccurrence of disease is higher in patients with central tolerance defect @baseline! B-cell return ‘as such’ is not predictive.
#ECTRIMS2024
Hogenboom (NL): first results of BLOOMS trial: standard vs extended interval dosing of ocrelizumab based on B-cell counts. No difference in efficacy (Relapses and MRI lesions)!
(Long term results to follow)
Big difference in intervals are seen (see slide)
#ECTRIMS2024
Müller Jannis: MSBase register study in de-escalation of treatment in #MS.
Increased risk of relapse reoccurring remains 2.3x higher.
No real cutoff for age, EDDS, disease duration or time from last relapse was found.
Note: Most were on natalizumab in this study!
#ECTRIMS2024
Bruijstens (NL): de-escalation (=reducing, not stopping) treatment in NMOSD/MOGAD.
Relapse risk decreases in MOGAD over time, but not in NMOSD (AQP4+). No real good option in the latter: relapse risk remains 9-38% (after stopping R/ 82%!!)
No good data on MOGAD.
#ECTRIMS2024
Starvaggi Cucuzza: anti-CD20 infection risk increased in female, smokers, high BMI, hypogammaglobulinemia and age.
Not really by treatment duration in itself.
De-escalation is an option (certainly in long disease duration and risk patients)
#ECTRIMS2024
Dosing interval extension is mostly used.
Studies are ongoing…(later today BLOOMS results) but first results are encouraging of maintaining effect (certainly on relapses and new lesions) en decreasing risk somewhat. (Hypogammaglob and vaccine response recovery)
#ECTRIMS2024